Imaging of Pilosebaceous Units and Acne Lesions by RCM and OCT Confocal Microscopy and Optical Coherence Tomography

May 11, 2018 updated by: Merete Haedersdal

Imaging of Pilosebaceous Units and Acne Lesions by Reflectance Confocal Microscopy and Optical Coherence Tomography

The purpose of the study was to investigate if reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) could be used in combination to investigate the morphology of pilosebaceous units and acne lesions in healthy subjects and in acne patients.Furthermore, to investigate contrast effects, biodistribution and selective photothermolysis provided by gold microparticles and diode laser pulses, using RCM, OCT and histology.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen NV, Denmark, 2400
        • Bispebjerg Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

All subjects

  1. Healthy men and women
  2. 18-45 years of age at baseline
  3. Legally competent, able to give verbal and written consent
  4. Communicate in Danish verbally as well as in writing
  5. Women with negative pregnancy-test
  6. Subject in good general health, is willing to participate and able to give informed consent, and can comply with protocol requirements.
  7. Fitzpatrick skin phototype I-III

Acne skin

  1. Subject with previous or prior clinical diagnosis of acne vulgaris, IGA score 1-4
  2. Subjects with 1 - 75 inflammatory facial lesions on the cheek, forehead, and/or chin, with no more than 2 nodulocystic lesions (see Appendix II, table 4)
  3. Each included patient with acne should represent at least 3 of 5 acne lesions
  4. Subject with in good general health, willing to participate and able to give informed consent, and able to comply with protocol requirements

Exclusion Criteria:

  1. Pregnant and lactating women
  2. Subject with a known allergy to gold, or any other ingredient in the microparticle suspension
  3. Individuals with skin diseases or skin lesions in the area of research interest will be excluded
  4. Subject with tattoo in the treatment area which may interfere with or confound evaluation of the study
  5. Subjects with severe acne (IGA 5) with imminent scarring potential, in the opinion of the investigator
  6. Subject with a history of keloids which is deemed clinically relevant in the opinion of the investigator
  7. Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or very severe acne requiring the continuation of systemic treatment during the study period.
  8. Subject with active skin disease or excessive scarring that, in the opinion of the investigator, would impact the ability to administer the gold microparticles or use of OCT/RCM in the areas
  9. Subject having used oral retionoid therapy such as isotretionoin within 3 months prior to baseline.
  10. Subject having used topical retinoids, topical corticosteroids, topical antibiotics or combination therapy within 2 weeks of baseline
  11. Subject having used over-the-counter topical products containing azelaic acid, benzoyl peroxide, and/or salicylic acid within 1 week of baseline
  12. Subject having used light treatments including Intense Pulsed Light or other lasers, microdermabrasion or chemical peels in the treatment area within 3 weeks of baseline.
  13. Subject who has received an investigational drug or was treated with an investigational device within 30 days prior to baseline.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NON_RANDOMIZED
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Acne patients
Application of gold microparticles to 2-3 facial areas
Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
EXPERIMENTAL: Heatlhy volunteers
Application of gold microparticles to 2 facial areas
Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acne morphology
Time Frame: 1 year
Qualitative assessment of acne lesions, pilosebaceous units and surrounding skin in RCM and OCT images
1 year
Gold microparticle biodistribution
Time Frame: 2 years
Evaluation of gold microparticle biodistribution and contrast effects in RCM and OCT images
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 1, 2016

Primary Completion (ACTUAL)

December 1, 2017

Study Completion (ACTUAL)

January 1, 2018

Study Registration Dates

First Submitted

May 1, 2018

First Submitted That Met QC Criteria

May 11, 2018

First Posted (ACTUAL)

May 14, 2018

Study Record Updates

Last Update Posted (ACTUAL)

May 14, 2018

Last Update Submitted That Met QC Criteria

May 11, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acne Vulgaris

Clinical Trials on SEB-250

Subscribe